Spinal opioids in adult patients with cancer pain: A systematic review: A European Palliative Care Research Collaborative (EPCRC) Opioid Guidelines Project
Restricted accessResearch articleFirst published online July, 2011
Spinal opioids in adult patients with cancer pain: A systematic review: A European Palliative Care Research Collaborative (EPCRC) Opioid Guidelines Project
Background: A systematic review, undertaken according to an initiative to revise European Association for Palliative Care guidelines on the use of opioids for cancer pain, which aimed to analyse analgesic efficacy and side effects of spinal opioids in adult cancer patients previously treated with systemic opioids.
Methods: Search strategy elaborated with MeSH terms and words related to cancer, palliative care, pain, spinal route and opioids. PubMed, Embase and Cochrane assessed in Nov 2009. Studies were analysed and classified according to quality of evidence and strength of recommendation.
Results: Out of 2939 abstracts, 44 articles were selected (nine randomized controlled trials (RCTs), two non-randomized cohort studies, 28 uncontrolled prospective studies, and five case series). Relief of pain and/or side effects were reported in 42 articles; however, there were few studies of high quality design (RCTs) and these studies had methodological limitations that reduced their quality of evidence to very low.
Conclusion: There are few RCTs and these are of very low quality. As a result, they provide weak recommendation for using spinal opioids in adult cancer patients. Further studies are clearly needed.
VentafriddaVTamburiniMCaraceniADe ConnoFNaldiF. A validation study of the WHO method for cancer pain relief. Cancer1987; 59: 850–856.
2.
KramesESGershowJGlassbergAKenefickTLyonsATaylorP. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer1985; 56: 696–702.
3.
BallantyneJCCarrDBBerkeyCSChalmersTCMostellerF. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Reg Anesth1996; 21: 542–556.
4.
BennettGSerafiniMBurchielKBuchserEClassenADeerT. Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage2000; 20: S12–36.
MyersJChanVJarvisVWalker-DilksC. Intraspinal techniques for pain management in cancer patients: a systematic review. Support Care Cancer2010; 18: 137–149.
7.
HanksGWConnoFChernyNHannaMKalsoEMcQuayHJ. Morphine and alternative opioids in cancer pain the EAPC recommendations. Br J Cancer2001; 84: 587–593.
8.
Oxford Centre of Evidence Based Medicine. Finding the evidence. Oxford: Centre for Evidence-Based Medicine, 2009. Available at http://www.cebm.net/?o=1038.
9.
FletcherRHFletcherSWWagnerEH. Clinical Epidemiology: The Essentials20054th ed. Baltimore: Lippincott Williams & Wilkins.
10.
AtkinsDBestDBrissPAEcclesMFalck-YtterYFlottorpS. Grading quality of evidence and strength of recommendations. Br Med J2004; 328: 1490–1490.
SmithTJStaatsPSDeerTStearnsLJRauckRLBoortz-MarxRL. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2002; 20: 4040–4049.
13.
SmithTJCoynePJStaatsPSDeerTStearnsLJRauckRL. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol2005; 16: 825–833.
14.
SmithTJCoynePJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med2005; 8: 736–742.
15.
GourlayGKPlummerJLCherryDAOnleyMMParishKAWoodMM. Comparison of intermittent bolus with continuous infusion of epidural morphine in the treatment of severe cancer pain. Pain1991; 47: 135–140.
16.
EisenachJCDuPenSDuboisMMiguelRAllinD. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain1995; 61: 391–399.
17.
KalsoEHeiskanenTRantioMRosenbergPHVainioA. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain1996; 67: 443–449.
18.
VainioATigerstedtI. Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques. Acta Anaesthesiol Scand1988; 32: 179–185.
19.
van DongenRTCrulBJvan EgmondJ. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain1999; 15: 166–172.
20.
LaurettiGRGomesJMReisMPPereiraNL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth1999; 11: 663–668.
21.
DriessenJJde MulderPHClaessenJJvan DiejenDWobbesT. Epidural administration of morphine for control of cancer pain: long-term efficacy and complications. Clin J Pain1989; 5: 217–222.
22.
OhlssonLRydbergTEdenTPerssonYThulinL. Cancer pain relief by continuous administration of epidural morphine in a hospital setting and at home. Pain1992; 48: 349–353.
23.
RauckRLCherryDBoyerMFKosekPDunnJAloK. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain2003; 4: 441–447.
24.
Du PenSLKharaschEDWilliamsAPetersonDGSloanDCHasche-KlunderH. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain1992; 49: 293–300.
PennRDPaiceJAGottschalkWIvankovichAD. Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. J Neurosurg1984; 61: 302–306.
27.
CoombsDWMaurerLHSaundersRLGaylorM. Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain control. J Clin Oncol1984; 2: 1414–1420.
28.
WangJK. Intrathecal morphine for intractable pain secondary to cancer of pelvic organs. Pain1985; 21: 99–102.
29.
ShetterAGHadleyMNWilkinsonE. Administration of intraspinal morphine sulfate for the treatment of intractable cancer pain. Neurosurgery1986; 18: 740–747.
30.
BoersmaFPNoorduinHVandenBG. Epidural sufentanil for cancer pain control in outpatients. Reg Anesth1989; 14: 293–297.
31.
HassenbuschSJPillayPKMagdinecMCurrieKBayJWCovingtonEC. Constant infusion of morphine for intractable cancer pain using an implanted pump. J Neurosurg1990; 73: 405–409.
32.
OnofrioBMYakshTL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg1990; 72: 200–209.
33.
WatermanNGHughesSFosterWS. Control of cancer pain by epidural infusion of morphine. Surgery1991; 110: 612–614.
34.
ErdineSAldemirT. Long-term results of peridural morphine in 225 patients. Pain1991; 45: 155–159.
35.
SchultheissRSchrammJNeidhardtJ. Dose changes in long- and medium-term intrathecal morphine therapy of cancer pain. Neurosurgery1992; 31: 664–669.
36.
WongCSChangYCYehCCHuangGSCherngCH. Loss of intrathecal morphine analgesia in terminal cancer patients is associated with high levels of excitatory amino acids in the CSF. Can J Anesth2002; 49: 561–565.
37.
MercadanteSArcuriEFerreraPVillariPMangioneS. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage2005; 30: 485–491.
38.
MercadanteSIntravaiaGVillariPFerreraPRiinaSDavidF. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain2007; 23: 793–798.
39.
ArnérSArnérB. Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand1985; 29: 32–36.
40.
SamuelssonHHednerT. Pain characterization in cancer patients and the analgetic response to epidural morphine. Pain1991; 46: 3–8.
41.
SjöbergMAppelgrenLEinarssonSHultmanELinderLENitescuP. Long-term intrathecal morphine and bupivacaine in “refractory” cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand1991; 35: 30–43.
42.
SjöbergMNitescuPAppelgrenLCurelaruI. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine: bupivacaine dose regimen of 0.5 : 4.75 mg/ml. Anesthesiology1994; 80: 284–297.
43.
MercadanteS. Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Symptom Manage1994; 9: 201–207.
44.
CaputiCABuscaGFogliardiFGiuglianoF. Evaluation of tolerance in long-term treatment of cancer pain with epidural morphine. Int J Clin Pharmacol Ther Toxicol1983; 21: 587–590.
45.
SamuelssonHMalmbergFErikssonMHednerT. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage1995; 10: 105–112.
46.
RicoRCHobikaGHAvellanosaAMTrudnowskiRJRempelJWestCR. Use of intrathecal and epidural morphine for pain relief in patients with malignant diseases: a preliminary report. J Med1982; 13: 223–231.
47.
NitescuPAppelgrenLLinderLESjöbergMHultmanECurelaruI. Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. J Pain Symptom Manage1990; 5: 18–26.
48.
SjøgrenPBanningA. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain1989; 39: 5–11.
49.
SamuelssonHEkmanRHednerT. CSF neuropeptides in cancer pain: effects of spinal opioid therapy. Acta Anaesthesiol Scand1993; 37: 502–508.
50.
CobbCAIIIFrenchBNSmithKA. Intrathecal morphine for pelvic and sacral pain caused by cancer. Surg Neurol1984; 22: 63–68.
51.
AhlgrenFIAhlgrenMB. Epidural administration of opiates by a new device. Pain1987; 31: 353–357.
52.
DennisGCDeWittyR. Management of intractable pain in cancer patients by implantable morphine infusion system. J Natl Med Assoc1987; 79: 939–944.
53.
BrazenorGA. Long-term intrathecal administration of morphine: a comparison of bolus injection via reservoir with continuous infusion by implanted pump. Neurosurgery1987; 21: 484–491.
StaatsP. Neural infusion for pain control: When, why, and what to do after the implant. Oncology1999; 13: 58–62.
56.
NitescuPSjöbergMAppelgrenLCurelaruI. Complications of intrathecal opioids and bupivacaine in the treatment of “refractory” cancer pain. Clin J Pain1995; 11: 45–62.
57.
RipamontiCBrueraE. Current status of patient-controlled analgesia in cancer patients. Oncology1997; 11: 373–380.
58.
MercadanteSBrueraE. Opioid switching: A systematic and critical review. Cancer Treat Rev2006; 32: 304–315.
59.
KehletHWilmoreDW. Multimodal strategies to improve surgical outcome. Am J Surg2002; 183: 630–641.
60.
DavisMWalshDLagmanRLeGrandSB. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2003; 21: 2800–2801; author reply 2802–2803.
61.
RipamontiCBrunelliC. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2003; 21: 2801–2802; author reply 2802–2803.
